Company profile: Theragenics
1.1 - Company Overview
Company description
- Provider of brachytherapy seed and surgical products. Offers Palladium-103 (TheraSeed) and Iodine-125 (AgX100) seeds for precise tumor radiation and localization (RSL), gold fiducial markers; wound closure products (sutures, needles), specialty needles; vascular and non-vascular access devices (introducers, catheters, guidewires); and consultancy for minimally invasive medical device design and manufacture.
Products and services
- AgX100 Iodine-125: Iodine-125 brachytherapy seeds configured for low-dose-rate treatments, facilitating precise radiation delivery to tumors
- Radioactive Seed Localization (RSL): Low-activity Iodine-125 seeds used for precise localization and removal of non-palpable breast tumors
- TheraSeed PD-103: Palladium-103 brachytherapy seeds used to deliver radiation directly to the tumor site while minimizing exposure to healthy tissue
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Theragenics
BioImagene
HQ: United States
Website
- Description: Provider of digital pathology solutions for clinical diagnostics and drug discovery, delivering integrated hardware and software systems to acquire, view, share, manage, archive, and analyze tissue images in pathology laboratories, including IHC algorithms such as HER2, ER/PR, and p53.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioImagene company profile →
Tharimmune
HQ: United Kingdom
Website
- Description: Provider of development-stage therapeutics for cancer and chronic pruritus, including TH104, a transmucosal buccal film with nalmefene targeting µ- and kappa-opioid receptors and inhibiting IL-17 for pruritus in PBC and other conditions; TH3215, a bispecific HER2/HER3 antibody; and TH1940, an anti-PD-1 Picobody therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tharimmune company profile →
Deciphera Pharmaceuticals
HQ: United States
Website
- Description: Provider of kinase inhibitor–based cancer medicines leveraging a proprietary switch-control platform. Commercializes Ripretinib (QINLOCK) for advanced gastrointestinal stromal tumor after treatment with three or more kinase inhibitors, and develops a pipeline including Vimseltinib (CSF1R) for TGCT, DCC-3116 (ULK1/2) for cancers with RAS/RAF mutations, DCC-3084 (pan-RAF), and DCC-3009 (next‑gen KIT).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Deciphera Pharmaceuticals company profile →
Aprea Therapeutics
HQ: Sweden
Website
- Description: Provider of oncology therapeutics focused on discovering and developing anticancer compounds that reactivate the tumor suppressor protein p53, including APR-246, a first-in-class small molecule drug candidate in clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aprea Therapeutics company profile →
Normunity
HQ: United States
Website
- Description: Provider of precision immuno-oncology medicines focused on immune normalizers—novel cancer immunotherapies that restore normal immune responses. Includes the Chen Lab Discovery Platform to identify and validate novel targets and Normunity Drug Development to create monoclonal antibodies based on these discoveries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Normunity company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Theragenics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Theragenics
2.2 - Growth funds investing in similar companies to Theragenics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Theragenics
4.2 - Public trading comparable groups for Theragenics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →